Clinical trials: Androgen Deprivation Therapy
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Prostate Carcinoma, Recurrent Prostate Carcinoma
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD)…
- Trial name
- NCT07202247
- Testing
- Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer Metastatic
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
STAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy.
- Trial name
- STAMPEDE2 (NCT06320067)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT)
- Where
- 18 sites in United Kingdom
- Volunteers
- 3,360 people
- Sponsor
- University College, London
Prostate Cancer
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called…
- Trial name
- ProsRSI (NCT04349501)
- Testing
- Restriction Spectrum Imaging Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Prostate Adenocarcinoma
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma.
- Trial name
- NCT03718338
- Testing
- Evaluation, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
This study is testing a walking program called Walk with Ease by the Arthritis Foundation with men undergoing treatment for prostate cancer.
- Trial name
- NCT02139774
- Testing
- Walk with Ease
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal…
- Trial name
- NCT07311915
- Testing
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Castration Sensitive Prostate Cancer
A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, intermittent Androgen…
- Trial name
- NCT06044025
- Testing
- Metformin, Turmeric
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Arkansas
Prostate Cancer
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Radiation and androgen deprivation is a common modality for patients with localized prostate cancer. Unfortunately for patients with intermediate to high risk prostate cancer incomplete tumor eradication and subsequent relapse…
- Trial name
- BrUOGPR255 (NCT01826838)
- Testing
- Dasatinib
- Sponsor
- Brown University
Prostate Cancer
An Alternative to A Fixed Schedule In Management Of Prostate Cancer
The male sex-hormone called testosterone is known to play a key role in the growth of prostate cancer. The usual treatment for the disease involves suppression of hormones (testosterone) by anti-hormonal treatment for an unknown…
- Trial name
- TADS (NCT01056562)
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Prostate Cancer Locally Advanced
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
This study evaluated long-term disease control and side effects of a moderately hypofractionated radiotherapy protocol for men with high-risk prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Locally Advanced, Prostatic Neoplams
- Trial name
- NCT07900555
- Testing
- Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation, Androgen Deprivation Therapy (ADT)
- Where
- Norway
- Volunteers
- 191 people
- Sponsor
- Haukeland University Hospital